Turkey – Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report View Sample

Published: February 24, 2022 Report Code: GDHC0026CHR-ST

Select Item

The pharmaceutical market size in Turkey was valued at $7.5 billion in 2020. The market is expected to grow further at a CAGR of less than 1% from 2021-2027. The Turkey healthcare market is potentially attractive for multinational firms seeking to invest in joint ventures and other types of mutually beneficial collaborations with their Turkish counterparts. Turkey’s favorable environment for pharmaceutical investments is driven by strong government support, manufacturing and R&D incentives, increasing per capita income, an expanding middle-class population, and other factors. The medical devices market was valued at $7 billion in 2021 and is predicted to expand at a CAGR of over 3% during 2022-27.

Overview of Turkey pharmaceuticals market

Overview of Turkey pharmaceuticals market

For more insights on this report, download a free report sample

Overview of Turkey medical devices market

Overview of Turkey medical devices market

For more insights on this report, download a free report sample

What are the market dynamics in the Turkey pharmaceuticals market?

The Turkish government is reforming its healthcare system to ensure that all residents have access to high-quality healthcare. The Turkish Ministry of Health (MoH) established the Strategic Plan 2019–2023 to preserve individual and community health at the highest level. MoH is using a person-centered approach and delivering timely, relevant, and effective solutions to health problems through high-quality treatment.

Development in the life expectancy of Turkish people is attributed to improved healthcare quality and accessibility, improved treatment of major illnesses such as cardiovascular, diabetes, and cancer, and fewer maternal and neonatal mortality.

What are the key sub-segments in the Turkey pharmaceuticals market?

The key sub-segments in the pharmaceuticals market in Turkey are generics, biologics, biosimilars, and over the counter (OTC).

Turkey pharmaceuticals market, by sub-segment

Turkey pharmaceuticals market, by sub-segment

For more pharmaceuticals sub-segment insights, download a free report sample

Who are the major players in the Turkey pharmaceuticals market?

Some of the major players in the pharmaceuticals market in Turkey are Bayer AG (Bayer), Novartis, Sanofi, Pfizer, and Gilead.

Bayer AG (Bayer)

The company discovers, develops, manufactures, and commercializes products for human healthcare and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. Bayer is headquartered in Leverkusen, Germany. In Turkey, it operates from Istanbul.

Novartis

It is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products. They also deal with eye care products. And drugs for the treatment of cancer and other diseases. Novartis is headquartered in Basel, Switzerland. In Turkey, it operates from Istanbul.

Sanofi

It is a healthcare company that researches, develops, manufactures, and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, and human vaccines for protection against various bacterial and viral diseases. Sanofi is headquartered in Paris, France. In Turkey, it operates from Beşiktaş, Istanbul.

Turkey pharmaceuticals market, by major players

Turkey pharmaceuticals market, by major players

To know more about major players in pharmaceuticals market, download a free report sample

What are the market dynamics in the Turkey medical devices market?

Turkey is a large importer of medical technologies, with medical devices accounting for 80% of total medical technology imports. Domestic medical devices companies primarily manufacture disposables, orthopedic implants, surgical tools, stents, prosthetics, surgical gowns, masks and drapes, and hospital furniture. In response to the worldwide COVID-19 pandemic, a Turkish collaboration led by Biosys created the first local mechanical ventilator which was widely deployed.

What are the sub-segments in the medical devices market of Turkey?

The key sub-segments in the medical devices market of Turkey are hospital supplies, cardiovascular devices, general surgery, orthopedic devices, and nephrology and urology devices. Hospital supplies has the highest share among them in the market.

Turkey medical devices market, by sub-segment

Turkey medical devices market, by sub-segment

For more medical devices sub-segment insights, download a free report sample

Who are the major players in the Turkey medical devices market?

Some of the major players in the medical devices market in  Turkey are Siemens Healthineers, GE Healthcare, Boston Scientific Corp (Boston Scientific), Terumo, and Getinge AB (Getinge).

Siemens Healthineers

It a subsidiary of Siemens AG. This medical technology company designs, develops, and distributes diagnostic imaging systems, clinical and workflow systems and solutions, and systems for minimally invasive procedures. Siemens Healthineers is headquartered in Erlangen, Germany. In Turkey, it operates from Esentepe, Istanbul.

GE Healthcare

It manufactures and sells medical imaging devices for diagnosis, as well as other medical devices. GE Healthcare is headquartered in Chicago, Illinois, US. In Turkey, it operates from Şişli, Istanbul.

Boston Scientific Corp (Boston Scientific)

This medical technology company develops, manufactures, and commercializes devices for a range of interventional medical specialties. The company offers products in the areas of electrophysiology, gastroenterology, among others. Boston Scientific is headquartered in Massachusetts, US. In Turkey, it operates from Uskudar, Istanbul.

Turkey medical devices market, by key players

Turkey medical devices market, by key players

To know more about medical devices market players, download a free report sample

Market report scope (pharmaceuticals market)

Market size (2020) $7.5 billion
Growth rate (2021-2027) CAGR of <1%
Forecast period 2021-2027
Segmentation by type Generics, Biologics, Biosimilars, and Over the Counter (OTC)
Key players Bayer AG (Bayer), Novartis, Sanofi, Pfizer, and Gilead

Market report scope (medical devices)

Market size (2021) $7 billion
Growth rate (2022 to 2027) CAGR of >3%
Forecast period 2022-2027
Segmentation by type Hospital Supplies, Cardiovascular Devices, General Surgery, Orthopedic Devices, and Nephrology and Urology Devices
Key players Siemens Healthineers, GE Healthcare, Boston Scientific Corp (Boston Scientific), Terumo, and Getinge AB (Getinge)

This report provides:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analysis of the major players in the pharmaceutical market: Bayer, Novartis, Sanofi, Pfizer, and Gilead.
  • Profiles and SWOT analysis of the major players in the medical device market: GE Healthcare, Siemens Healthineers, Boston Scientific, Terumo, and Getinge.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Turkish healthcare market.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the Turkish healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact Turkish healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Turkey Healthcare Market

2.3 Key Highlights: Healthcare Startups in Turkey, 2021

2.4 Key Events: Healthcare Industry, Turkey, 2015–2021

2.5 Key Events: Turkey Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–2021

2.7 Key Events: Top Completed Deals by Value, 2020–2021

2.8 Country Profile, Turkey, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Turkey

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas – Turkey

3.7 COVID-19 Epidemiology, Turkey

3.8 COVID-19 Impact and Developments, Turkey

3.9 COVID-19 Impact and Developments in the Healthcare Market, Turkey

3.10 COVID–19 Clinical Trials Landscape, Turkey

3.11 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Turkey, 2017–2021

6.2 Deal Analysis: Medical Device Market, Turkey, 2017–2021

7. HealthTech Landscape

7.1 HealthTech Landscape, Turkey

7.2 Digital Statistics, Turkey

7.3 Adoption of Technology in Healthcare, Turkey

7.4 HealthTech Deals Landscape, Turkey

7.5 Key HealthTech Deals, Turkey

7.6 Digital Regulations, Turkey

7.7 HealthTech Landscape: Benefits and Risks, Turkey

8. Market Access

8.1 Overview of Healthcare System, Turkey

8.2 Overview of Insurance Providers, Public Insurance, Turkey

8.3 Overview of Insurance Providers, Private Insurance, Turkey

8.4 Reimbursement Process, Turkey

8.5 Out-of-Pocket Spending and Healthcare Price Index, Turkey

8.6 Pricing Policies, Turkey

8.7 Regulatory Landscape, Turkey

8.7.1 Marketing Authorization for Pharmaceutical Products, Turkey

8.7.2 Marketing Authorization for Generic Medicines, Turkey

8.7.3 Marketing Authorization for Biologics, Turkey

8.7.4 Marketing Authorization for Biosimilars, Turkey

8.7.5 Marketing Authorization for Medical Devices, Turkey

8.7.6 Intellectual Property Rights, Patent, Turkey

8.7.7 Intellectual Property Rights, Trademark, Turkey

8.7.8 Clinical Trial Regulations, Turkey

8.7.9 Pharmaceutical Clinical Trials Landscape, Turkey

8.7.10 Medical Devices Clinical Trials Landscape, Turkey

8.7.11 Pharmacy License Regulations, Turkey

8.7.12 Pharmaceutical Advertising Regulations, Turkey

8.7.13 Labeling and Packaging Regulations, Turkey

9. Country Healthcare Landscape

9.1 Turkish Healthcare Policy Highlights

9.2 Healthcare Facilities, Turkey

9.3 Healthcare Parameters, Turkey

9.4 Life Expectancy and Immunization Rate, Turkey

9.5 Environmental Health, Turkey

9.6 Healthcare Personnel, Turkey

9.7 Disease Burden, Turkey

9.8 Healthcare Expenditure, Turkey

10 Trade Associations, Turkey

11 Trade Fairs, Turkey

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: COVID-19 indicators (number), Turkey and Global, 2022

Table 2: Travel restrictions imposed during COVID-19, Turkey, 2020–22

Table 3: Available COVID–19 vaccines, Turkey, 2021

Table 4: Medical devices market, major segments ($M), Turkey, 2021

Table 5: Overview of telehealth programs in Turkey, 2015

Table 6: Social security premiums (%), Turkey, 2021

Table 7: Pharmacy discount rates, Turkey, 2021

Table 8: Profit rates for drug pricing, Turkey, 2021

Table 9: Medical devices classification, Turkey, 2020

Table 10: Medical device registration, Turkey, 2020

Table 11: Patent application fee, Turkey, 2022

Table 12: Trademark application fee, Turkey, 2022

Table 13: Clinical trial application fee, Turkey, 2021

Table 14: Trade fairs, Turkey, 2022

Figures

Figure 1: Pharmaceutical market, revenue ($B and TL B), Turkey, 2015–21

Figure 2: Medical device market, revenue ($B), Turkey, 2016–21

Figure 3: Healthcare startups in Turkey, 2021

Figure 4: Country profile, Turkey, 2021

Figure 5: Pharmaceutical market, revenue ($B and TL B), Turkey, 2015–21

Figure 6: Pharmaceutical market, revenue forecast ($B and TL B), Turkey, 2022–27

Figure 7: Pharmaceutical exports ($B), Turkey, 2014–20

Figure 8: Top export partners, Turkey, 2020

Figure 9: Pharmaceutical imports ($B), Turkey, 2014–20

Figure 10: Top import partners, Turkey, 2020

Figure 11: Pharmaceutical distribution channels, Turkey, 2021

Figure 12: Generic drugs usage (% share by value), Turkey, 2014–21

Figure 13: Generic drugs usage (% share by volume), Turkey, 2014–21

Figure 14: OTC medicines market, major distribution channels ($M), Turkey, 2021

Figure 15: OTC medicines market, revenue ($B), Turkey, 2014–21

Figure 16: OTC medicines market, major categories ($M), Turkey, 2021

Figure 17: OTC market by sub-categories of drugs, revenue ($M), Turkey, 2021

Figure 18: Major therapeutic areas by pharmaceutical consumption (DDD/1,000 person/day), Turkey, 2019

Figure 19: Major therapeutic areas by market size (%), Turkey, 2019

Figure 20: Major therapeutic areas by pharmaceutical sales ($M), Turkey, 2017–19

Figure 21: COVID-19 (number of cases), Turkey, 2020–22

Figure 22: COVID-19 (number of deaths), Turkey, 2020–22

Figure 23: Stringency index, COVID-19, Turkey, 2020–22

Figure 24: Containment and health index, COVID-19, Turkey, 2020–22

Figure 25: COVID-19 Fiscal stimulus packages, Turkey, 2020–21

Figure 26: COVID-19 Vaccine doses administration, number of vaccine doses administered, Turkey, 2022

Figure 27: Top COVID-19 markets by product categories (number of available marketed products), Turkey, 2020–22

Figure 28: Top COVID-19 IVD products by device class (number of available marketed products), Turkey, 2020–22

Figure 29: Top COVID-19 products by equipment type (number of available marketed products), Turkey, 2020–22

Figure 30: Top COVID-19 Point of Care test products by equipment type (number of available marketed products), Turkey, 2020–22

Figure 31: COVID-19 clinical trials sponsors by trial count, Turkey, 2020–22

Figure 32: COVID-19 clinical trials count by phase, Turkey, 2020–22

Figure 33: COVID-19 clinical trials count by trial status, Turkey, 2020–22

Figure 34: Medical devices market, revenue ($B), Turkey, 2016–21

Figure 35: Medical devices market, revenue forecast ($B), Turkey, 2022–27

Figure 36: Medical devices market, major segments (%), Turkey, 2021

Figure 37: Hospital supplies market, revenue ($B), Turkey, 2017–26

Figure 38: Cardiovascular devices market, revenue ($M), Turkey, 2017–26

Figure 39: General surgery market, revenue ($M), Turkey, 2017–26

Figure 40: Orthopedic devices market, revenue ($M), Turkey, 2017–26

Figure 41: Nephrology and urology devices market, revenue ($M), Turkey, 2017–26

Figure 42: Diagnostics market, revenue ($B), Turkey, 2017–21

Figure 43: Diagnostics market, revenue forecast ($B), Turkey, 2022–26

Figure 44: Medical devices market, revenue ($B) of major companies, Turkey, 2020

Figure 45: Deal value and deal count, pharmaceutical market, Turkey, 2017–21

Figure 46: Deal value and deal count, quarterly, pharmaceutical market, Turkey, 2017–21

Figure 47: Deal value and deal count subtypes, pharmaceutical market, Turkey, 2017–21

Figure 48: Top therapy areas by deal value ($M), pharmaceutical market, Turkey, 2017–21

Figure 49: Top therapy areas by deal count, pharmaceutical market, Turkey, 2017–21

Figure 50: M&A deals, bi-annually, (by value and by number), pharmaceutical market, Turkey, 2017–21

Figure 51: PE deals by quarter (by value and by number), pharmaceutical market, Turkey, 2017–21

Figure 52: Deal value and deal count, medical devices market, Turkey, 2017–21

Figure 53: Deal value and deal count, quarterly, medical devices market, Turkey, 2017–21

Figure 54: Deal value and deal count subtypes, medical devices market, Turkey, 2017–21

Figure 55: Top equipment sectors by deal value ($M), medical devices market, Turkey, 2017–21

Figure 56: Top equipment sectors by deal count, medical devices market, Turkey, 2017–21

Figure 57: M&A deals, bi-annually, (by value and by number), medical devices market, Turkey, 2017–21

Figure 58: VC deals by quarter (by value and by number), medical devices market, Turkey, 2017–21

Figure 59: Overview of electronic health records (EHR) usage in Turkey, 2021

Figure 60: Deal value ($M) and deal count (number of deals), HealthTech, Turkey, 2015–21

Figure 61: Deal value ($M) and deal count (number of deals) by sector, HealthTech, Turkey, 2015–21

Figure 62: Legal frameworks for e-Health, Turkey, 2021

Figure 63: Organizational structure of Ministry of Health, Turkey, 2021

Figure 64: Social Security System, Turkey, 2021

Figure 65: Healthcare services under universal health insurance, Turkey, 2021

Figure 66: SWOT analysis of the private health insurance system, Turkey, 2021

Figure 67: Reimbursement process, Turkey, 2021

Figure 68: Out-of-pocket spending ($ per capita), Turkey, 2014–21

Figure 69: Change in health price index (% change accumulated in the year), Turkey, 2014–21

Figure 70: Medicine pricing process, Turkey, 2021

Figure 71: Organization structure of Turkish Medicine and Medical Device Agency, Turkey, 2021

Figure 72: Marketing authorization of pharmaceutical products, Turkey, 2020

Figure 73: Trademark registration process, Turkey, 2021

Figure 74: Pharmaceutical clinical trials count by trial status, Turkey, 2020–22

Figure 75: Pharmaceutical clinical trials count by phase, Turkey, 2020–22

Figure 76: Pharmaceutical clinical trials count by indication, Turkey, 2020–22

Figure 77: Top five pharmaceutical clinical trials sponsors by count, Turkey, 2020–22

Figure 78: Medical devices clinical trials count by trial status, Turkey, 2020–22

Figure 79: Medical devices clinical trials count by indication, Turkey, 2020–22

Figure 80: Medical devices clinical trials count by device category, Turkey, 2020–22

Figure 81: Top five medical devices clinical trials sponsors by trial count, Turkey, 2020–22

Figure 82: Packaging and labeling information, Turkey, 2021

Figure 83: Policies and therapies to lessen the burden of noncommunicable diseases, Turkey, 2013–21

Figure 84: Number of hospitals, Turkey, 2014–21

Figure 85: Number of public and private hospitals, Turkey, 2014–21

Figure 86: Number of hospital beds (per 1,000 population), Turkey, 2014–21

Figure 87: Number of acute care beds (per 1,000 population), Turkey, 2014–21

Figure 88: Number of PET scanners and mammographs (per million population), Turkey, 2014–21

Figure 89: Number of CT scanners and MRI units (per million population), Turkey, 2014–21

Figure 90: Immunization rate (%), Turkey, 2014–21

Figure 91: Life expectancy at birth (years), Turkey, 2014–21

Figure 92: CO2 emissions (million tons), Turkey, 2014–21

Figure 93: PM2.5 (µg per m3), Turkey, 2014–21

Figure 94: Physicians (per 1,000 population), Turkey, 2014–21

Figure 95: Dentists (per 1,000 population), Turkey, 2014–21

Figure 96: Pharmacists (per 1,000 population), Turkey, 2014–21

Figure 97: Nurses (per 1,000 population), Turkey, 2014–21

Figure 98: Major causes of mortality (per 100,000 population), Turkey, 2019

Figure 99: Major causes of male mortality (per 100,000 population), Turkey, 2019

Figure 100: Major causes of female mortality (per 100,000 population), Turkey, 2019

Figure 101: DALYs by major disease (per 100,000 population), Turkey, 2019

Figure 102: Healthcare expenditure as percentage of GDP (%), Turkey, 2014–21

Figure 103: Health expenditure share (% of total health spending), Turkey, 2014–21

Frequently asked questions

Turkey – Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,992

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Turkey – Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Pharmaceuticals
New
Atopic Dermatitis (Atopic Eczema) Clinical Trial Analysis by Phase, Trial…
$2,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Turkey – Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Turkey – Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more